NIH, National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) NIH - National Institutes of Health National Cancer Institute DCTD - Division of Cancer Treatment and Diagnosis

Multiplex Immunofluorescence (mIF): Analytical Validation for Vectra Panels 1 and 2 (MD Anderson)    Add to my SOP compendium

BRD ID: 3,110

Source: CIMAC-CIDC Network Tier: SOP Number of times downloaded: 118

Description

1.0 (6-3-2019) This assay analytical validation and performance report describes the methods used to validate the multiplex immunofluorescence (mIF) assay for automated staining and analysis with Vectra panels 1 and 2 (Pancytokeratin AE1/AE3, CD3, CD8, CD68, PD1, PD-L1, GZB, CD45RO, and FOXP3) in formalin-fixed, paraffin-embedded (FFPE) tissue sections. The document also presents data supporting (1) the reported accuracy, precision, analytical sensitivity and specificity, and reportable range and (2) the reported accuracy, variation, and sensitivity data of mIF results in FFPE blocks stored for different durations and slides containing FFPE sections that were stored for two years. It is used by a Cancer Immune Monitoring and Analysis Center (CIMAC) at the MD Anderson Cancer Center. It is a product of the CIMAC and Cancer Immunologic Data Center Network (CIMAC-CIDC Network; https://dctd.cancer.gov/ResearchNetworks/cimacs_cidc_network.htm), a Cancer Moonshot Initiative.

Documents for Download

Analytical report_Multiplex IF_06032019_MDACC_508_Final rep.pdf [Size: 1833 KB]

Biospecimens
  • Cell - Kidney
  • Cell - Lung
  • Cell - Placenta
  • Cell - Tonsil
  • Cell - Breast
Diagnoses
  • Normal
  • Neoplastic - Carcinoma
Topics
  • Biospecimen Preservation
  • Biospecimen Processing
  • Storage
  • Platform-specific Methodology

Associated SOP Compendiums

News and Announcements

  • New Articles on the GTEx Project are Now FREELY Available!

  • Just Published!

  • April 24, 2024: Biobanking for Precision Medicine Seminar

  • More...